DEG-77 是一种靶向 IKZF2 和 CK1α 的分子胶降解剂,DC50 分别为 15.3 nM 和 10 nM,具有显著的抗肿瘤活性,可诱导促凋亡蛋白 Bax 和细胞周期阻滞蛋白 p21 的转录水平升高,可用于急性髓系白血病 (AML)、弥漫性大 B 细胞淋巴瘤和卵巢癌的研究。
产品编号: MS-Z29678 纯度: 99.03% CAS No.: 3032265-06-5 分子式: C24H21N3O6 分子量: 447.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

DEG-77 是一种靶向 IKZF2 和 CK1α 的分子胶降解剂,DC50 分别为 15.3 nM 和 10 nM,具有显著的抗肿瘤活性,可诱导促凋亡蛋白 Bax 和细胞周期阻滞蛋白 p21 的转录水平升高,可用于急性髓系白血病 (AML)、弥漫性大 B 细胞淋巴瘤和卵巢癌的研究。

生物实验数据

生物活性 DEG-77 is a molecular glue degrader targeting IKZF2 and CK1α with DC50 values of 15.3 nM and 10 nM, respectively, and exhibits significant antitumor activity by inducing elevated transcriptional levels of the pro-apoptotic protein Bax and the cell cycle arrest protein p21, making it applicable for research on acute myeloid leukemia (AML), diffuse large B-cell lymphoma, and ovarian cancer.
IC50 & Target

CK1α

10 nM (DC50)

IZKF2

15.3 nM (DC50)

Bax

 

体外研究
(In Vitro)

DEG-77 (1-1000 nM;0.5-24 h) 在野生型 DLD1、U2OS、A549 和 TOV-21G 细胞中可诱导 CK1α、SACK1B、高磷酸化 SACK1D、SACK1F 及 SACK1G 发生剂量和时间依赖性的共同降解,但 SACK1H 不受影响,其中在 100 nM 处理 24 h 时可观察到显著的蛋白耗竭。
DEG-77 (100 nM;6 h) 介导的 CK1α、SACK1B、SACK1F 和 SACK1G 的共降解在 CRBN-/-和 CSNK1A1-/- DLD1 人结直肠癌细胞中被完全阻断,表明该过程依赖于 CRBN 和 CK1α 的表达。
DEG-77 (100 nM;6 h) 在野生型 DLD1 人结直肠癌细胞中介导的 CK1α、SACK1B、SACK1F 和 SACK1G 的共降解依赖于蛋白酶体活性,但不依赖于自噬。
DEG-77 (100 nM; 24 h) 可在稳定工程化的 HEK293T 细胞中强效且选择性地降解 IKZF2 与 CK1α,对 IKZF1 和 GSPT1 的降解作用极弱。
DEG-77 (50 nM;2 h) 可诱导 MOLM-13 急性髓系白血病细胞中 CK1α 的选择性降解,并激活 p53。
DEG-77 (100 pM-10 μM;5 d) 可在 5 天内抑制 A2780 卵巢癌细胞和 OCI-LY3 弥漫大 B 细胞淋巴瘤细胞的活力,其 EC50 为 27 和 14 nM。
DEG-77 (1 nM-10 μM;24 h) 可在 A2780 卵巢癌细胞中降解 CK1α 与 IKZF2,在 OCI-LY3 弥漫大 B 细胞淋巴瘤细胞中可降解 CK1α但对 GSPT1 无降解作用。
DEG-77 (1 μM; 24 h) 可上调 A2780 卵巢癌细胞和 OCI-LY3 弥漫性大 B 细胞淋巴瘤细胞中 Bax 和 p21 的转录水平,这表明 p53 被激活。

Western Blot Analysis

Cell Line: wild-type human DLD1 colorectal cancer cells
Concentration: 1, 10, 100, 500 and 1000 nM
Incubation Time: 0.5-24 h
Result: Robustly depleted CK1α, SACK1F, and SACK1G protein levels, caused a substantial reduction in the 100 kDa hyperphosphorylated (CK1α-bound) form of SACK1D without affecting unphosphorylated SACK1D, and caused a modest reduction in SACK1B levels at 100 nM for 24 h.
Induced a dose-dependent co-depletion of CK1α, SACK1B, hyperphosphorylated SACK1D, SACK1F, and SACK1G, with robust reduction observed at 100 nM and above across 1-1000 nM for 24 h.\n

Induced a time-dependent reduction in CK1α, SACK1B, hyperphosphorylated SACK1D, SACK1F, and SACK1G levels at 100 nM over 0.5-24 h, with CK1α reduction observed as early as 30 min, robust depletion after 1 h, peak degradation at 3 h, and depletion sustained for 24 h.\n

Left SACK1H levels unchanged across all conditions.

Western Blot Analysis

Cell Line: wild-type human U2OS osteosarcoma cells, wild-type human A549 lung adenocarcinoma cells, wild-type human TOV-21G ovarian cancer cells
Concentration: 1, 10, 100, 500 and 1000 nM
Incubation Time: 0.5-24 h
Result: Induced a dose-dependent co-depletion of CK1α, hyperphosphorylated SACK1D, and SACK1G in all three cell lines, with robust reduction observed at 100 nM and above across 1-1000 nM for 24 h.\n

Reduced SACK1B levels in a dose-dependent manner in U2OS and A549 cells across 1-1000 nM for 24 h.\n

Induced a time-dependent reduction in CK1α, hyperphosphorylated SACK1D, and SACK1G levels in all three cell lines at 100 nM over 0.5-24 h, with depletion kinetics mirroring that seen in DLD1 cells.\n

Reduced SACK1B levels in a time-dependent manner in U2OS and A549 cells at 100 nM over 0.5-24 h.\n

Left SACK1H levels unchanged across all cell lines and conditions.

Western Blot Analysis

Cell Line: wild-type human DLD1 colorectal cancer cells, CRBN-/- human DLD1 colorectal cancer cells, CSNK1A1-/- (CK1α knockout) human DLD1 colorectal cancer cells
Concentration: 100 nM
Incubation Time: 6 h
Result: Depleted CK1α, SACK1B, SACK1F, and SACK1G levels in wild-type DLD1 cells.\n

Did not deplete CK1α, SACK1B, SACK1F, or SACK1G levels in CRBN-/- DLD1 cells.\n

Did not deplete SACK1B, SACK1F, or SACK1G levels (CK1α was not detectable) in CSNK1A1-/- DLD1 cells.

Western Blot Analysis

Cell Line: wild-type human DLD1 colorectal cancer cells
Concentration: 100 nM
Incubation Time: 4 h (following 2 h pre-incubation with inhibitor)
Result: Had its mediated depletion of CK1α, SACK1B, SACK1F, and SACK1G levels completely rescued by pre-treatment with 20 μM MG132.\n

Had its mediated depletion of CK1α, SACK1B, SACK1F, and SACK1G levels not rescued by pre-treatment with 50 nM bafilomycin A1.

Western Blot Analysis

Cell Line: human control skin fibroblasts (FIB03), palmoplantar keratoderma patient-derived skin fibroblasts (FIB04, homozygous SACK1G^R265P mutation with disrupted CK1α binding)
Concentration: 100 nM
Incubation Time: 24 h
Result: Robustly depleted CK1α and SACK1G levels, and reduced hyperphosphorylated SACK1D levels in control FIB03 fibroblasts.

Robustly depleted CK1α levels and reduced hyperphosphorylated SACK1D levels, but did not deplete SACK1G^R265P levels in patient-derived FIB04 fibroblasts.

Western Blot Analysis

Cell Line: SACK1G-/- human DLD1 colorectal cancer cells stably transduced with SACK1G-GFP, SACK1G-/- human DLD1 colorectal cancer cells stably transduced with SACK1G^R265P-GFP
Concentration: 100 nM
Incubation Time: 6 h
Result: Robustly depleted CK1α and SACK1F levels in all transduced cells.\n

Robustly depleted SACK1G-GFP levels in cells expressing SACK1G-GFP.\n

Did not deplete SACK1G^R265P-GFP levels in cells expressing SACK1G^R265P-GFP.

Western Blot Analysis

Cell Line: A2780 ovarian cancer cells and OCI-LY3 diffuse large B cell lymphoma cells
Concentration: 1, 10, 100 nM, 1, 10 μM
Incubation Time: 24 h
Result: Induced degradation of CK1α, with relative ratio reduced to 0.17 at all concentrations ≥ 1 nM.
Induced degradation of IKZF2, with relative ratio reduced to 0.06 at 10 μM.
Did not induce degradation of GSPT1 at any tested concentration.

Real Time qPCR

Cell Line: A2780 ovarian cancer cells and OCI-LY3 diffuse large B cell lymphoma cells
Concentration: 1 μM
Incubation Time: 24 h
Result: Increased transcript levels of pro-apoptotic protein Bax.
Increased transcript levels of cell cycle arrest protein p21.
Left CK1α transcript levels unchanged.
性状 固体
颜色 Light yellow to green yellow

化学信息

分子量 447.44
分子式 C24H21N3O6
CAS No. 3032265-06-5

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (111.75 mM; 超声助溶 (<80°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.2349 mL11.1747 mL22.3494 mL55.8734 mL
5 mM0.4470 mL2.2349 mL4.4699 mL11.1747 mL
10 mM0.2235 mL1.1175 mL2.2349 mL5.5873 mL
15 mM0.1490 mL0.7450 mL1.4900 mL3.7249 mL
20 mM0.1117 mL0.5587 mL1.1175 mL2.7937 mL
25 mM0.0894 mL0.4470 mL0.8940 mL2.2349 mL
30 mM0.0745 mL0.3725 mL0.7450 mL1.8624 mL
40 mM0.0559 mL0.2794 mL0.5587 mL1.3968 mL
50 mM0.0447 mL0.2235 mL0.4470 mL1.1175 mL
60 mM0.0372 mL0.1862 mL0.3725 mL0.9312 mL
80 mM0.0279 mL0.1397 mL0.2794 mL0.6984 mL
100 mM0.0223 mL0.1117 mL0.2235 mL0.5587 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础